0001193125-21-001034.txt : 20210204 0001193125-21-001034.hdr.sgml : 20210204 20210104163953 ACCESSION NUMBER: 0001193125-21-001034 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: (302) 547-3768 MAIL ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 CORRESP 1 filename1.htm CORRESP

January 4, 2021

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Deanna Virginio

 

Re:

Prelude Therapeutics Incorporated

  

Registration Statement on Form S-1 (File No. 333-251874)

  

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:30 p.m. Eastern Time, on Wednesday, January 6, 2020 or as soon thereafter as practicable.

[Signature page follows]

Very truly yours,

Morgan Stanley & Co. LLC

Goldman Sachs & Co. LLC

BofA Securities, Inc.

As representatives of the Underwriters

 

By:

  

Morgan Stanley & Co. LLC

By:   /s/ Chris Rigoli
  Name:   Chris Rigoli
  Title:   Vice President

By:

  

Goldman Sachs & Co. LLC

By:   /s/ Elizabeth Wood
  Name:   Elizabeth Wood
  Title:   Managing Director

By:

  

BofA Securities, Inc.

By:   /s/ Greg Butz
  Name:   Greg Butz
  Title:   Managing Director

[Signature Page to Prelude Therapeutics Incorporated Acceleration Request]